Keratoconus: cross-linking the window of the eye

Sally Hayes, Siân R. Morgan and Keith M. Meek

Abstract: Keratoconus is a condition in which the cornea progressively thins and weakens, leading to severe, irregular astigmatism and a significant reduction in quality of life. Although the precise cause of keratoconus is still not known, biochemical and structural studies indicate that overactive enzymes within the cornea break down the constituent proteins (collagen and proteoglycans) and cause the tissue to weaken. As the disease develops, collagen fibres slip past each other and are redistributed across the cornea, causing it to change shape. In recent years, it was discovered that the photochemical induction of cross-links within the corneal extracellular matrix, through the use of riboflavin and ultraviolet (UVA) light, could increase the strength and enzymatic resistance of the tissue and thereby halt keratoconus progression. Worldwide acceptance and use of riboflavin/UVA corneal cross-linking therapy for halting keratoconus progression has increased rapidly, in accordance with the growing body of evidence supporting its long-term effectiveness. This review focusses on the inception of riboflavin/UVA corneal cross-linking therapy for keratoconus, its clinical effectiveness and the latest scientific advances aimed at reducing patient treatment time, improving patient comfort and increasing patient eligibility for treatment.

Plain language summary

Review of current treatments using cross-linking to halt the progress of keratoconus

Keratoconus is a disease in which the curved cornea, the transparent window at the front of the eye, weakens, bulges forward into a cone-shape and becomes thinner. This change of curvature means that light is not focussed onto the retina correctly and vision is progressively impaired. Traditionally, the effects of early keratoconus were alleviated by using glasses, specialist contact lenses, rings inserted into the cornea and in severe cases, by performing a corneal transplant. However, it was discovered that by inducing chemical bonds called cross-links within the cornea, the tissue could be strengthened and further thinning and shape changes prevented. The standard cross-linking procedure takes over an hour to perform and involves the removal of the cells at the front of the cornea, followed by the application of Vitamin B2 eye drops and low energy ultraviolet light (UVA) to create new cross-links within the tissue. Clinical trials have shown this standard procedure to be safe and effective at halting keratoconus progression. However, there are many treatment modifications currently under investigation that aim to reduce patient treatment time and increase comfort, such as accelerated cross-linking procedures and protocols that do not require removal of the surface cells. This review describes the different techniques being developed to carry out corneal cross-linking efficiently and painlessly, to halt keratoconus progression and avoid the need for expensive surgery.

Keywords: collagen, cornea, cross-linking, keratoconus, riboflavin, UVA
Background

Keratoconus is a condition in which the cornea becomes progressively thinner and weaker over time, leading to an outward bulging of the tissue and severe, irregular astigmatism. Although keratoconus is a relatively rare disease that does not normally result in blindness, it does have a significant impact on public health due to its early age of onset and the severely detrimental impact that it has on patient quality of life. The condition typically manifests in young adults in their teens to early twenties and in some, but not all, cases it may progress for up to 10–20 years thereafter, with the rate of progression commonly being greater in pediatric patients (<18 years of age) than in other age groups. Estimates of keratoconus prevalence vary from 17 to 4000 per 100,000 of the general population, with the large variation being attributed to differences in geographical location, diagnostic methods, sample size and study design.

Although the precise cause of keratoconus and the mechanism by which it progresses remain a matter of uncertainty, a number of environmental and genetic risk factors have been identified, such as excessive eye rubbing, atopy and a family history of keratoconus. In addition to these risk factors, the keratoconus cornea also exhibits a number of biochemical and structural abnormalities that likely contribute to disease progression. For example, collagen degradation is enhanced in the keratoconic cornea by the presence of higher than normal levels of proteolytic enzymes and reduced levels of proteinase inhibitors. Additionally, X-ray scattering studies of advanced stage keratoconus corneas have revealed abnormalities in the arrangement and distribution of the stromal collagen lamellae that form the bulk of the cornea and are believed to help the healthy cornea withstand the forces acting upon it to maintain its curvature. Such findings indicate that inter-fibrillar and inter-lamellar slippage, and a redistribution of collagen mass are involved in the progressive thinning and steepening in keratoconus corneas, a process which would undoubtedly be facilitated by the enhanced degradation of collagen in these corneas, as well as by the reduced lamellar interweaving and fewer lamellar insertions into Bowman’s membrane that are associated with the condition.

Visual function may be improved through the use of glasses or specialist contact lenses, or through the insertion of intra-corneal ring segments (Intacs or Ferrara Rings) or a flexible, full ring intra-corneal implant (MyoRing), which flattens the curvature of the keratoconus cornea and, in the case of the MyoRing, may also strengthen and stabilise the weakened tissue. However, these management tools alone are unable to address both the enhanced enzymatic digestion and tissue weakening associated with keratoconus to stop the natural progression of the condition. In approximately 12% of cases, invasive surgical treatment in the form of a full or partial thickness corneal transplant is required due to severe disease advancement, contact lens intolerance and/or corneal scarring. In 2012, a survey of 184,576 corneal transplants performed in 116 countries revealed keratoconus to be one of the leading indications for corneal transplantation (accounting for 27% of all transplants). Whilst corneal transplantation has a notably high success rate (with graft survival rates of >90% at 13 years), the procedure requires a protracted recovery time, the use of corticosteroids to prevent rejection and the continued use of rigid contact lenses to restore visual function. Corneal transplantation also carries the risk of serious complications such as infection, graft failure (and in rare cases recurrent keratoconus) and, as a treatment option, it is susceptible to worldwide shortages of donor corneas. Although transplantation remains the dominant, end of line, surgical intervention for advanced keratoconus, management of the condition has changed dramatically since the early 2000s with the introduction of photochemical corneal cross-linking therapy – a minimally invasive treatment proven to halt early-stage progressive keratoconus. This review will focus on the development and recent advances in corneal cross-linking therapy for keratoconus.

Inception of corneal cross-linking therapy for keratoconus

Since keratoconus progression is rarely seen in patients >40 years old due to the natural stiffening of the cornea with age (as glycation-induced cross-links become more prevalent within the stromal extracellular matrix), it was postulated that artificially cross-linking the extracellular matrix of the keratoconus corneal stroma might provide a protective effect against enzymatic degradation and fibrillar slippage. Spoor et al. went on to show that application of a photosensitiser (riboflavin) in conjunction with a 30-min exposure to 370 nm ultraviolet (UVA; corresponding to one of the absorption maxima
S Hayes, SR Morgan et al.

of riboflavin), resulted in significant corneal stiffening and an increased resistance of the tissue to enzymatic digestion.25,26

Riboflavin-5 phosphate (vitamin B2) was selected as the photosensitiser of choice on the basis of its water solubility and biocompatibility, and the fact that it readily diffuses into the corneal stroma when the epithelium is removed. Riboflavin plays a crucial role in the cross-linking process; it enhances cross-link formation and absorbs UVA as it passes through the corneal stroma, thereby protecting the deeper ocular structures, such as the lens and retina, from damage.27 Oxygen is also highly important to the process.28 When exposed to UVA light, the riboflavin is excited to singlet and triplet states, and follows one of two photochemical reactions. The Type I mechanism predominates at low oxygen concentrations and results in the generation of riboflavin free radical species, which interact with molecular oxygen in the ground state and form oxidation products. At higher oxygen concentrations (present at the start of the procedure), the Type II mechanism predominates, with riboflavin transferring energy to oxygen in the ground state to generate more reactive singlet molecular oxygen, which then reacts with stromal extracellular components to induce covalent cross-link formation.29 Extensive laboratory studies of the interactions between collagens and proteoglycans during cross-linking,30,31 coupled with investigations into the hydrodynamic behaviour and structure of cross-linked corneas, indicate that the cross-links are most likely formed within and between collagen molecules on the fibril surfaces, and within the proteoglycan core proteins that reside between the collagen fibrils.32

**Clinical effectiveness and limitations of the standard cross-linking protocol**

The standard cross-linking procedure, often referred to as the ‘Dresden protocol’, is an ‘epithelium-off’ technique that requires a minimal corneal thickness of 400 µm to ensure sufficient shielding of the endothelium, lens and retina.27 At the start of the procedure, the central 8 mm of the corneal epithelium is fully removed to facilitate the penetration of riboflavin solution (comprising 0.1% riboflavin-5-phosphate and 20% dextran) into the stroma. During a 30-min instillation period, the riboflavin solution is re-applied at frequent intervals to ensure saturation of the stroma. The cornea is then irradiated with 3 mW/cm² of UVA for 30-min (total radiance of 5.4 J/cm²), with continued re-application of riboflavin throughout (Figure 1).

Wollensak et al. first demonstrated the clinical potential of corneal cross-linking for the management of progressive keratoconus in a pilot study involving 23 cases of moderate to advanced keratoconus, in which a cessation of progression was reported in all cases.33 The safety and effectiveness of the procedure was subsequently supported by a number of other non-randomised studies (the largest of which involved 272 patients34), and randomised-controlled trials (RCTs; summarised in Table 1). The treatment has been shown to have no effect on endothelial cell density and morphology at 5-year follow up,35 and the pre-operative thickness and stratification of the corneal epithelium is restored within 3–6 months of treatment.36 Although cross-linking results in a loss of keratocytes from the anterior and mid-stroma (up to a depth of ~300 µm) within 24 h of treatment,37 the effect is temporary, with stromal keratocyte repopulation being initiated within 3–6 months and reaching completion within 6 months.38 At approximately 1 month post-treatment a demarcation line (an area of hyper-reflectivity) is visible, with anterior segment optical coherence tomography and confocal microscopy at a depth of ~300 µm. Some have suggested that this line may be a wound-healing effect, whilst others have purported that it may represent the border between treated and untreated tissue (and therefore be used as an indicator of the effective depth of cross-linking).39 However, in a recent study in which an ultra-high speed Scheimpflug camera coupled with a non-contact tonometer (Corvis...
Table 1. RCTs (>12 months) examining the efficacy of standard protocol riboflavin/UVA corneal cross-linking in halting keratoconus progression.

| Source               | Study parameters                                      | Primary outcomes                                                                 | Study limitations                                                                                     |
|----------------------|-------------------------------------------------------|----------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|
| Greenstein et al.41  | 71 eyes (49 with keratoconus; 22 with post-LASIK ectasia); 12-month follow up | CXL group: improvement in 4/7 topography indices indicating improved corneal shape. Untreated fellow eye and sham controls: no change in topography from baseline. | Relatively short follow-up; participants in the control group allowed to cross-over to the treatment group after 3-months; patients with keratoconus and ectasia treated as a single cohort |
| O’Brart et al.42     | 24 participants with early/moderate bilateral keratoconus; 18-month follow up | CXL group: ↓ corneal steepness; no evidence of keratoconus progression. Untreated fellow eyes: majority remained stable but evidence of keratoconus progression in 14% of eyes. | It was not possible to mask the participants due to the invasive nature of the treatment. |
| Wittig-Silva et al.43| 100 eyes with progressive keratoconus; 36-month follow up | CXL group: overall ↓ corneal steepness (Kmax ↓ 1.03D) and a cessation of keratoconus progression in all but one eye. Untreated controls: Kmax ↑ 1.75D | After 6 months, control group participants with evidence of keratoconus progression were allowed to cross over into the treatment group leading to a possible underestimation of the treatment effect. |
| Lang et al.44        | 29 eyes with early progressive keratoconus; 36 months  | CXL group: overall ↓ corneal steepness (Kmax ↓ 0.35D/year) but in 4/15 patients there was a yearly ↑ Kmax of 0.02–0.32D. Sham treated controls: evidence of corneal steepening in 8/14 patients | Relatively small sample size due to recruitment issues as participants became increasingly unwilling to accept sham procedures. |
| Seyedian et al.45    | 26 patients with bilateral keratoconus; 12-month follow up | CXL group: overall ↓ corneal steepness (Kmax ↓ 0.2D); cessation of keratoconus progression in all three eyes. Untreated fellow eye: Kmax ↑ 0.4D | Relatively short follow up. It was not possible to mask the participants due to the invasive nature of the treatment. |
| Hersh et al.46       | 205 patients with progressive keratoconus; 12 months  | CXL group: overall ↓ corneal steepness (Kmax ↓ 1.6D); Kmax ↓ by 2.0 D or more in 28 eyes (31.4%) and ↑ by 2.0 D or more in 5 eyes (5.6%). Sham treated controls: continuation of keratoconus progression | Relatively short follow up. Participants in the control group were allowed to cross over to the treatment group at 3 months; only two control eyes remained at 12-months follow up. |

BCVA, best corrected visual acuity; CXL, cross-linking; Kmax, measurement of treatment outcomes: maximum simulated keratometry; LASIK, laser-assisted in situ keratomileusis; RCT, randomised controlled trial; UVA, ultraviolet.

ST) was used to measure in vivo dynamic corneal response parameters in 66 cross-linked keratoconus corneas, it was concluded that the precise location of the demarcation line did not appear to be related to corneal stiffening.40

The long-term corneal stabilisation and sustained improvement in corrected distance visual acuity achieved with the standard cross-linking protocol has been evidenced in numerous clinical studies with follow-up times of up to 10 years.34,47,48 However, in a small minority of cases, uncontrolled and continued long-term flattening of corneal curvature has been reported.40 Despite the evident success of the ‘standard’ cross-linking protocol for halting keratoconus progression, it is not without limitations. For example, it requires a relatively long treatment time (~1 h), patients with corneas of <400 µm are not eligible for treatment, and the removal of the epithelium causes significant patient discomfort and carries a risk of infection.50,51 These factors have driven the development of accelerated and transepithelial cross-linking procedures that offer the advantage of...
increased patient comfort, easier treatment of children and less co-operative patients, and improved cost-effectiveness.

Development of accelerated cross-linking protocols

Based on the Bunsen-Roscoe Law of reciprocity, it was proposed that the same biological effect as achieved with the standard (3 mW/cm² for 30 min) protocol could be accomplished using a higher fluence for a shorter period of time, so long as the total energy dose of 5.4 J/cm² was kept constant for example, 9 mW/cm² UVA for 10 min, 18 mW/cm² UVA for 5 min or 30 mW/cm² UVA for 3 min. Laboratory investigations into the effectiveness of accelerated cross-linking (ACXL) protocols have produced somewhat conflicting results. For example, the stress-strain measurements of Schumacher et al. from strips of cross-linked porcine corneas showed that a 9-min exposure to 10 mW/cm² UVA resulted in a similar increase in corneal stiffness as that achieved with the standard protocol. However, Hammer et al. showed that, although a 10-min exposure to 9 mW/cm² UVA stiffened the porcine cornea, it was to a lesser extent than that achieved with the standard protocol, and the stiffness of corneas cross-linked with 18 mW/cm² for 5 min did not differ from that of untreated corneas. In vivo measurements of human dynamic corneal response at 2-years post-cross-linking indicate that both the 9 mW/cm² (10 min) and 18 mW/cm² (5 min) procedures result in significant corneal stiffening, and ex vivo studies show increased enzymatic resistance following standard and ACXL protocols (up to 18 mW/cm² for 5 min) with only subtle differences between treatments. However, the enzymatic resistance of corneas treated with the standard protocol was far greater than those treated with 30 mW/cm² for 5 min, suggesting a reduced cross-linking effect and a failure of the Bunsen–Roscoe law of reciprocity at higher UVA intensities.

RCTs have demonstrated the efficacy of ACXL (9 mW/cm², 18 mW/cm² and 30 mW/cm²) at halting keratoconus progression in the short term and at 4 years follow up, cross-linking with 18 mW/cm² for 5 min was found to be similarly effective as the standard procedure. However, more RCTs are required to confirm the long-term efficacy of this and other ACXL procedures (especially those using very high UVA intensities).

Pulsed and oxygen supplemented cross-linking protocols

It has been suggested that the apparent failure of the Bunsen–Roscoe Law of reciprocity at very high levels of UVA intensity may be due to the more rapid oxygen depletion that occurs when using such high intensity UVA as well as to the fixed rate of oxygen diffusion into the cornea, limiting the cross-linking process. This has led to a further wave of suggested ACXL treatment modifications, including the extension of the exposure time by 30–40% to increase the overall energy dose. The potential benefit of an extended ACXL procedure is supported by laboratory studies showing that increasing the exposure time from 3 to 4 min during 30 mW/cm² ACXL (and thereby increasing the total energy dose from 5.4 to 7.2 J/cm²), significantly enhances corneal enzymatic resistance.

Other treatment modifications have focussed on enhancing oxygen availability during ACXL through the use of an oxygen delivery device to boost the atmospheric oxygen concentration at the corneal surface, or a pulsed UVA exposure (cycling the UVA light on and off), which theoretically aids the replenishment of stromal oxygen concentrations when using higher irradiances. Indeed, it has been shown that the enzymatic resistance of porcine corneas cross-linked with 30 mW/cm² UVA in a pulsed mode of 10-s on and 10-s off for a period of 8-min (total energy dose of 7.2 J/cm²) is slightly superior to that achieved when the same UVA intensity and energy dose is delivered in a non-pulsed manner. Many studies have reported that pulsed ACXL results in a significantly deeper stromal demarcation line than continuous ACXL, and that exposure to pulsed UVA can result in greater apoptotic effects and higher tissue damage than continuous delivery. In a study by Said et al. involving 49 progressive keratoconus patients, the use of pulsed ACXL [8-min exposure to 30 mW/cm² UVA (1 s on/1 s off)] resulted in severe localised corneal haze and residual scarring in 19% patients. However, despite their scarcity, the majority of clinical trials involving pulsed ACXL are supportive of its use, showing a similar or increased efficacy compared with continuous ACXL with a follow-up time of 2 years.
up to 2 years.67,73–75 Most recently, in a large study involving a 2-year follow up of 870 patients (1192 eyes) cross-linked using pulsed ACXL [8-min exposure (1.5 s on/1.5 s off) to 30 mW/cm² UVA], the treatment was shown to successfully halt keratoconus progression, with keratometric stabilization being reported in 98.3% of eyes.76 All the aforementioned procedures have involved delivery of a broad beam of irradiation to the surface of the cornea. However, early results suggest that greater efficacy may be achieved using topography-guided customized cross-linking (PiXL), in which high fluence cross-linking is performed in a customizable pattern with the intensity based on the patients’ refractive error and corneal topography.77

**Modifications to the riboflavin solution**

**Dextran-free riboflavin solutions**

It has been shown, both experimentally and clinically, that the application of riboflavin solutions containing 20% dextran can lead to significant corneal thinning due to the deturgescent effect of the dextran.56,75 Although the reduction in corneal thickness may be rectified prior to UVA exposure by the application of a hypo-osmolar riboflavin solution, the use of dextran-free riboflavin solutions, in which hydroxypropyl methylcellulose (HPMC) is used as a replacement riboflavin carrier solution, are becoming increasingly popular alternatives. Unlike dextran, which has a high affinity for water and causes the cornea to dehydrate and thin, HPMC is a water soluble, viscoelastic polymer that has little effect on corneal hydration and thickness. Also riboflavin solutions containing HPMC have a faster diffusion rate and tend to require a much shorter soak time than those containing dextran.79 Our experimental findings from porcine eyes have shown that a small but nevertheless significant (p < 0.01) amount of corneal thinning occurs following a 20-min application of an isotonic riboflavin solution containing 1.1% HPMC but the thinning effect is much less than occurs with application of a riboflavin-dextran solution (Figure 2).

Clinically, the application of riboflavin-HPMC appears to have little effect on corneal thickness, causing it to decrease only slightly or, in some cases, increase.80–82 It has been suggested that a shallower depth of cross-linking may be expected with use of riboflavin-HPMC compared with riboflavin-dextran due to the differences in corneal thickness at the time of UVA exposure and the UVA transmission being higher in the thinner, riboflavin-dextran treated corneas.79 However, in a prospective RCT involving 40 eyes and a 2-year follow up, improvements in visual acuity and maximum keratometry were found following both standard cross-linking and ACXL (9 mW/cm² UVA for 10-min) with riboflavin-HPMC.83 Similarly, in another RCT involving 48 eyes cross-linked with 3 mW/cm² UVA for 30 min, no significant differences in maximum keratometry, visual acuity, corneal thickness or endothelial cell count were evident at 12-month follow up between eyes treated with riboflavin-dextran and those treated with riboflavin-HPMC.81 Although clinical studies are generally supportive of its use, further research is required into the long-term efficacy of riboflavin-HPMC/UVA cross-linking.

**Transepithelial riboflavin solutions**

Transepithelial cross-linking, in which riboflavin is applied through an intact epithelium, has many potential benefits over the standard, epithelium-off procedure, being less invasive, carrying a reduced risk of infection and enabling easier treatment of paediatric and uncooperative patients. However, the effectiveness of the procedure is dependent upon there being a sufficient and homogenous distribution of riboflavin within the corneal stroma, a relatively unblocked transmission of UVA radiation through the epithelium and adequate stromal oxygen re-diffusion.

Laboratory studies have shown that minimal stromal penetration of riboflavin (containing dextran) occurs when the porcine epithelium is intact or
even partially disrupted,84–86 as the high molecular weight of dextran inhibits the penetration of riboflavin across the epithelium. As a result, commercially available transepithelial riboflavin solutions tend to be dextran-free, with HPMC as a replacement carrier solution, and also contain permeation enhancers, such as benzalkonium chloride (BAC), trometamol or edetate disodium (EDTA), to loosen the tight junctions of the epithelial cells and facilitate passage of riboflavin into the stroma (Table 2). However, these additives can be toxic to the epithelium, with the impact being both duration and concentration dependent.87

Although numerous laboratory studies have indicated that the cross-linking effect is greatly reduced in porcine corneas when transepithelial solutions are used compared with when riboflavin is applied directly to the stromal surface, the amount of cross-linking achieved may nevertheless be sufficient to stop keratoconus progression.88,89 Clinical studies of transepithelial effectiveness are notoriously difficult to compare due to differences in multiple aspects of the cross-linking procedure (riboflavin solution, UVA intensity and duration, etc.), as well as differences in the reported outcome measures and follow-up times. For example, Filipello et al. treated 20 patients using a transepithelial application of a riboflavin solution containing dextran, trometamol and EDTA, and an exposure to 3 mW/cm^2 UVA for 30 min and reported that the treatment appeared to be safe and well tolerated, halted keratoconus progression and improved both visual and topographic parameters at 18-month follow up.90 Caporossi et al. performed the same procedure on 26 keratoconus eyes and reported improvements in visual acuity within the first 6-months post-treatment but a gradual return to pre-treatment levels and evidence of keratoconus instability and function regression within 24 months.91 In a prospective, interventional multi-centre cohort study involving 26 patients cross-linked transepithelially with a high concentration riboflavin solution containing BAC 0.01%, Gatzioufas et al. reported significant epithelium damage in the immediate post-operative period and evidence of keratoconus progression in 46% of

| Table 2. Commercially available CE-marked riboflavin solutions for keratoconus cross-linking. |
|---------------------------------------------------------------|
| **Riboflavin formulation** | **Composition** |
| Epi-off, isotonic | Mediocross D | 0.1% riboflavin 5-phosphate, 20% dextran |
| | Ricrolin | 0.1% riboflavin 5-phosphate, 20% dextran |
| | Ribocross | 0.1% riboflavin, 20% dextran |
| | Vibex Rapid | 0.1% riboflavin-5-phosphate, HPMC |
| | Mediocross M | 0.25% riboflavin-5-phosphate, HPMC |
| Epi-off, hypotonic | Mediocross H | 0.1% riboflavin-5-phosphate |
| | Ricrolin+ | 0.1% riboflavin, EDTA, trometamol |
| Epi-on (Transepithelial) | Paracel | 0.25% riboflavin-5-phosphate, HPMC, BAC, EDTA |
| | Mediocross TE | 0.25% riboflavin-5-phosphate, HPMC, BAC |
| | Ricrolin TE | 0.1% riboflavin-5-phosphate, dextran, trometamol, EDTA |
| | Ribocross TE | 0.1% riboflavin-5-phosphate, dextran, Vitamin E-TPGS |
| | Ricrolin+ | 0.1% riboflavin-5-phosphate, trometamol, EDTA |
| | Ribofast | 0.1% riboflavin-5-phosphate, Vitamin E-TPGS |

It should be noted that the recommended application procedure varies greatly between different riboflavin solutions; e.g. 1 drop every 30 s for 15 min for Ribofast and Ribocross TE, 1 drop every 2 min for 30 min for Ricrolin TE and Ricrolin+, with the recommended soak time being reduced to just 5 min for an iontophoresis-assisted delivery of Ricrolin+. BAC, benzalkonium chloride; EDTA, edetate disodium; HPMC, hydroxyl propyl methylcellulose; Vitamin E-TPGS, d-alpha-tocopheryl polyethylene-glycol succinate.
Therapeutic Advances in Rare Disease 2

eyes at 12-month follow up. Following a meta-analysis of 1-year follow-up outcomes from seven RCTs (total of 505 eyes) it was concluded that the standard procedure had a greater impact on halting keratoconus progression than transepithelial ACXL. This finding has been supported by a 5-year follow-up study of 78 paediatric, progressive keratoconus patients in which it was shown that both standard cross-linking and transepithelial ACXL (using a 0.25% riboflavin solution containing HPMC and 0.007% BAC, and a 5-min exposure to 18 mW/cm² UVA) successfully halted keratoconus progression, but the standard protocol was deemed safer and more effective.

Recently, promising results have been reported by Zaheryani et al. in a double-blinded, randomised study in which 30 patients treated with epithelium-off ACXL (with a preservative and dextran-free riboflavin solution and a 10-min exposure to 9 mW/cm² UVA) in one eye and, in the other, a Daya epithelium disruptor (Duckworth and Kent Ltd, Baldock, UK) was used to create tiny pores in the epithelium to facilitate the absorption of the same riboflavin solution into the stroma prior to cross-linking. The results at 12-month follow up showed that the potential for halting keratoconus progression did not differ between the two techniques.

Iontophoresis-assisted riboflavin delivery represents another development in transepithelial cross-linking. With this technique, a low intensity electric field (0.5–1.0 mA) is used to facilitate the transport of the low molecular weight, negatively charged riboflavin solution across the intact epithelium and into the stroma (Figure 3). It has been demonstrated in rabbits that iontophoresis-assisted delivery of 0.1% riboflavin using a current of 1 mA for 5 min followed by a 30-min, 3 mW/cm² UVA exposure, results in a stromal riboflavin concentration that is two-fold lower than that achieved with the standard, epithelium-off protocol but produces a similar increase in corneal stiffness and resistance to collagenase digestion. However, it should be noted that studies involving rabbit eyes provide a somewhat liberal estimate of transepithelial cross-linking efficacy because their corneal epithelium is thinner than that of the human cornea (~40 μm versus 50 μm), and studies using porcine eyes result in a more conservative measure due to their thicker epithelium (~90 μm). Indeed, contrary to the findings in rabbit eyes, it has been shown in porcine corneas that ACXL involving a 5-min iontophoresis-assisted delivery of riboflavin and 9 mW/cm² UVA for 10 min does not produce the same level of enhanced resistance to enzymatic digestion as achieved with epithelium-off ACXL.

Clinically, it has been shown that iontophoresis-assisted cross-linking produces significant visual improvements in the short term, but the corneal apex flattening is less than that achieved with epithelium-off approaches. Further to this, a 3-year follow up of paediatric patients found that the epithelium-off approach (using 10 mW/cm² for 9 min) resulted in a cessation of keratoconus progression in 75% of eyes, whereas iontophoresis-assisted cross-linking slowed down keratoconus progression in only 50% of eyes.

Based on studies of enzymatic resistance in cross-linked porcine corneas, it has been shown that the outcome of transepithelial cross-linking may be improved significantly through the use of higher riboflavin concentrations, a longer duration of iontophoresis and an increase in UVA radiance. These findings led to the development and optimisation of the St. Thomas’/Cardiff iontophoresis protocol, which essentially involves two transepithelial, iontophoresis-assisted deliveries of a
0.25% riboflavin solution with permeation enhancers (Mediocross TE Veni Vidi (Halifax, UK)), separated by a soakage period to allow time for stromal riboflavin diffusion, and followed by an exposure to 9 mW/cm² UVA for 12 min and 30 s (total radiant exposure 6.75 J/cm²). In vitro, this technique was found to be superior to that of other transepithelial protocols in terms of increasing resistance of the porcine cornea to enzymatic digestion and was closest to that of epithelium-off cross-linking. Further, long-term, randomised controlled studies are warranted to ascertain the true effectiveness of this, and other, transepithelial cross-linking procedures.

**Treatment modifications for very thin corneas**

In advanced cases of keratoconus, the thickness of the cornea may be less than the 400 µm required for the standard cross-linking protocol. Various treatment modifications have been proposed for cross-linking such thin corneas, and these are covered comprehensively in a separate review. However, by way of a summary, they include the use of a hypo-osmolar riboflavin solution to swell the cornea prior to cross-linking; the use of transepithelial riboflavin solutions and/or iontophoresis-assisted riboflavin delivery to maximise the thickness of the tissue; the use of higher riboflavin concentrations to reduce the amount of UVA radiation reaching the deeper layers of the cornea and reduce the risk of endothelial toxicity; the use of pachymetry-guided epithelial debridement (‘epithelial island technique’) to selectively remove the epithelium from regions of the cornea with a thickness >400 µm; the use of a shielding riboflavin-soaked contact lens (‘contact lens-assisted cross-linking’); or the use of refractive stromal lenticules spread over the cornea to thicken the thinnest parts of the cornea (‘lenticule assisted cross-linking’). In addition to this, the potential of other non-UVA cross-linking procedures is being investigated. In particular, near infra-red illumination of a water-soluble bacteriochlorophyll derivative has been shown to produce a comparable enhancement of enzymatic resistance and tissue stiffness with that achieved with riboflavin/UVA cross-linking, and may in future offer a means of safely treating keratoconus corneas of any thickness. However, as is the case with all deviations from the standard cross-linking protocol, long-term studies and further research are required to validate the safety and efficacy of these treatments.

**Combination cross-linking ‘plus’ procedures for keratoconus**

In a bid to effectively halt keratoconus progression and improve functional visual outcomes, the use of corneal cross-linking in combination with refractive procedures, such as topography-guided photorefractive keratectomy (PRK) and intra-corneal ring segment or continuous ring implantation, have become increasingly popular. Studies involving these combination therapies, collectively and commonly referred to as ‘CXL Plus’ procedures, have all shown some degrees of success. However, in many cases, the reliability of the evidence in these studies is limited by small sample sizes, the observational nature of the study design and the absence of control groups to demonstrate significant benefit of the combined procedure over and above that of the individual procedures. RCTs are therefore required to further confirm the long-term safety and effectiveness of these promising CXL Plus therapeutic approaches.

**Author contributions**

Sally Hayes: Conceptualization; formal analysis; investigation; writing-original draft.

Siân R Morgan: Conceptualization; writing-review and editing.

Keith Meek: Funding acquisition; writing-review and editing.

**Conflict of interest statement**

The authors declare that there is no conflict of interest.

**Funding**

The authors are supported by a Medical Research Council Grant (MR/S037829/1) awarded to Prof Meek.

**ORCID iD**

Sally Hayes [https://orcid.org/0000-0001-8550-0108]

**References**

1. Kymes SM, Walline JJ, Zadnik K, et al. Changes in the quality-of-life of people with keratoconus. *Am J Ophthalmol* 2008; 145: 611–617.
2. Romano V, Vinciguerra R, Arbabi EM, et al. Progression of keratoconus in patients while awaiting corneal cross-linking: a prospective clinical study. *J Refract Surg* 2018; 34: 177–180.

3. Hashemi H, Heydarian S, Hooshmand E, et al. The prevalence and risk factors for keratoconus: a systematic review and meta-analysis. *Cornea* 2020; 39: 263–270.

4. Davidson AE, Hayes S, Hardcastle AJ, et al. The pathogenesis of keratoconus. *Eye (Lond)* 2014; 28: 189–195.

5. Sawaguchi S, Twining SS, Yue BYJT, et al. Alpha-1 proteinase inhibitor inhibitor levels in keratoconus. *Exp Eye Res* 1990; 50: 549–554.

6. Sawaguchi S, Yue BY, Sugar J, et al. Lysosomal enzyme abnormalities in keratoconus. *Arch Ophthalmol* 1989; 107: 1507–1510.

7. Hayes S, Boote C, Tuft SJ, et al. A study of corneal thickness, shape and collagen organisation in keratoconus using videokeratography and X-ray scattering techniques. *Exp Eye Res* 2007; 84: 423–434.

8. Meek KM, Tuft SJ, Huang Y, et al. Changes in collagen orientation and distribution in keratoconus corneas. *Invest Ophthalmol Vis Sci* 2005; 46: 1948–1956.

9. Daxer A and Fratzl P. Collagen fibril orientation in the human corneal stroma and its implication in keratoconus. *Invest Ophthalmol Vis Sci* 1997; 38: 121–129.

10. Aghamohammadzadeh H, Newton RH and Meek KM. X-ray scattering used to map the preferred collagen orientation in the human cornea and limbus. *Structure* 2004; 12: 249–256.

11. Boote C, Dennis S, Huang Y, et al. Lamellar orientation in human corneas in relation to mechanical properties. *J Struct Biol* 2005; 149: 1–6.

12. Radner W, Zehetmayer M, Skorpik C, et al. Altered organization of collagen in the apex of keratoconus corneas. *Ophthalmic Res* 1998; 30: 327–332.

13. Morishige N, Wahlert AJ, Kenney MC, et al. Second-harmonic imaging microscopy of normal human and keratoconus cornea. *Invest Ophthalmol Vis Sci* 2007; 48: 1087–1094.

14. Downie LE and Lindsay RG. Contact lens management of keratoconus. *Clin Exp Optom* 2015; 98: 299–311.

15. Piñero DP and Alio JL. Intracorneal ring segments in ectatic corneal disease - a review. *Clin Exp Ophthalmol* 2010; 38: 154–167.

16. Daxer A, Ettl A and Hörantner R. Long-term results of MyoRing treatment of keratoconus. *J Optom* 2017; 10: 123–129.

17. Daxer A. Biomechanics of corneal ring implants. *Cornea* 2015; 34: 1493–1498.

18. Gordon MO, Steger-May K, Szczotka-Flynn L, et al. Baseline factors predictive of incident penetrating keratoplasty in keratoconus. *Am J Ophthalmol* 2006; 142: 923–930.e921.

19. Gain P, Jullienne R, He Z, et al. Global survey of corneal transplantation and eye banking. *JAMA Ophthalmol* 2016; 134: 167–173.

20. Pramanik S, Musch DC, Sutphin JE, et al. Extended long-term outcomes of penetrating keratoplasty for keratoconus. *Ophthalmology* 2006; 113: 1633–1638.

21. Kelly TL, Williams KA and Coster DJ. Corneal transplantation for keratoconus: a registry study. *Arch Ophthalmol* 2011; 129: 691–697.

22. Yoshida J, Murata H, Miyai T, et al. Characteristics and risk factors of recurrent keratoconus over the long term after penetrating keratoplasty. *Graefes Arch Clin Exp Ophthalmol* 2018; 256: 2377–2383.

23. Kennedy RH, Bourne WM and Dyer JA. A 48-year clinical and epidemiologic study of keratoconus. *Am J Ophthalmol* 1986; 101: 267–273.

24. Malik NS, Moss SJ, Ahmed N, et al. Aging of the human corneal stroma - structural and biochemical changes. *Biochim Biophys Acta* 1992; 1138: 222–228.

25. Spoerl E, Huhle M and Seiler T. Induction of cross-links in corneal tissue. *Exp Eye Res* 1998; 66: 97–103.

26. Spoerl E, Wollensak G and Seiler T. Induction of cross-links in corneal tissue. *Exp Eye Res* 1998; 66: 97–103.

27. Spoerl E, Wollensak G and Seiler T. Increased resistance of crosslinked cornea against enzymatic digestion. *Curr Eye Res* 2004; 29: 35–40.

28. Spoerl E, Mrochen M, Slomey D, et al. Safety of UVA-riboflavin cross-linking of the cornea. *Cornea* 2007; 26: 385–389.

29. Richoz O, Hammer A, Tabibian D, et al. The biomechanical effect of corneal collagen cross-linking (CXL) with riboflavin and UV-A is oxygen dependent. *Transl Vis Sci Technol* 2013; 2: 6.

30. Zhang Y, Conrad A and Conrad G. Effects of ultraviolet-A and riboflavin on the interaction of
collagen and proteoglycans during corneal cross-linking. *J Biol Chem* 2011; 286: 13011–13022.

31. Meek KM and Hayes S. Corneal cross-linking—a review. *Ophthalmic Physiol Opt* 2013; 33: 78–93.

32. Hayes S, Kamma-Lorger C, Boote C, et al. The effect of riboflavin/UVA collagen cross-linking therapy on the structure and hydrodynamic behaviour of the ungulate and rabbit corneal stroma. *PLoS One* 2013; 8: e52860.

33. Wollensak G, Spoerl E and Seiler T. Riboflavin/ultraviolet-A-induced collagen crosslinking for the treatment of keratoconus. *Am J Ophthalmol* 2003; 135: 620–627.

34. Raiskup-Wolf F, Hoyer A, Spoerl E, et al. Collagen crosslinking with riboflavin and ultraviolet-A light in keratoconus: long-term results. *J Cataract Refract Surg* 2008; 34: 796–801.

35. Kymionis GD, Grentzelos MA, Liakopoulos DA, et al. Long-term follow-up of corneal collagen cross-linking for keratoconus—the Cretan study. *Cornea* 2014; 33: 1071–1079.

36. Mazzotta C, Caporossi T, Denaro R, et al. Morphological and functional correlations in riboflavin UV A corneal collagen cross-linking for keratoconus. *Acta Ophthalmol* 2012; 90: 259–265.

37. Wollensak G, Spoerl E, Wilsch M, et al. Keratocyte apoptosis after collagen cross-linking using riboflavin/UVA treatment. *Cornea* 2004; 23: 43–49.

38. Mazzotta C, Balestrazzi A, Traversi C, et al. Treatment of progressive keratoconus by riboflavin-UVA-induced cross-linking of corneal collagen: ultrastructural analysis by Heidelberg Retinal Tomograph II in vivo confocal microscopy in humans. *Cornea* 2007; 26: 390–397.

39. Spadea L, Tonti E and Vingolo EM. Corneal stromal demarcation line after collagen cross-linking in corneal ectatic diseases: a review of the literature. *Clin Ophthalmol* 2016; 10: 1803–1810.

40. Vinciguerra R, Tzamalis A, Romano V, et al. Assessment of the association between in vivo corneal biomechanical changes after corneal cross-linking and depth of demarcation line. *J Refract Surg* 2019; 35: 202–206.

41. Greenstein SA, Fry KL and Hersh PS. Corneal topography indices after corneal collagen crosslinking for keratoconus and corneal ectasia: one-year results. *J Cataract Refract Surg* 2011; 37: 1282–1290.

42. O’Brat DP, Chan E, Samaras K, et al. A randomised, prospective study to investigate the efficacy of riboflavin/ultraviolet A (370 nm) corneal collagen cross-linkage to halt the progression of keratoconus. *Br J Ophthalmol* 2011; 95: 1519–1524.

43. Wittig-Silva C, Chan E, Islam FMA, et al. A randomized, controlled trial of corneal collagen cross-linking in progressive keratoconus: three-year results. *Ophthalmology* 2014; 121: 812–821.

44. Lang SJ, Messmer EM, Geerling G, et al. Prospective, randomized, double-blind trial to investigate the efficacy and safety of corneal cross-linking to halt the progression of keratoconus. *BMC Ophthalmol* 2015; 15: 78.

45. Seyedian MA, Aliakbari S, Miraftab M, et al. Corneal collagen cross-linking in the treatment of progressive keratoconus: a randomized controlled contralateral eye study. *Middle East Afr J Ophthalmol* 2015; 22: 340–345.

46. Hersh PS, Stulting RD, Muller D, et al. U.S. multicenter clinical trial of corneal collagen crosslinking for treatment of corneal ectasia after refractive surgery. *Ophthalmology* 2017; 124: 1475–1484.

47. O’Brat DP, Patel P, Lascaratos G, et al. Corneal cross-linking to halt the progression of keratoconus and corneal ectasia: seven-year follow-up. *Am J Ophthalmol* 2015; 160: 1154–1163.

48. Caporossi A, Mazzotta C, Baiocchi S, et al. Long-term results of riboflavin ultraviolet a corneal collagen cross-linking for keratoconus in Italy: the Siena eye cross study. *Am J Ophthalmol* 2010; 149: 585–593.

49. Noor I, Seiler TG, Noor K, et al. Continued long-term flattening after corneal cross-linking for keratoconus. *J Refract Surg* 2018; 34: 567–570.

50. Ghanem VC, Ghanem RC and de Oliveira R. Postoperative pain after corneal collagen cross-linking. *Cornea* 2013; 32: 20–24.

51. Hersh PS, Stulting RD, Muller D, et al. United States multicenter clinical trial of corneal collagen crosslinking for keratoconus treatment. *Ophthalmology* 2017; 124: 1259–1270.

52. Bunsen R and Roscoe H. Photochemical researches - Part V. On the measurement of the chemical action of direct and diffuse sunlight. *Proc R Soc Lond* 1862; 12: 306–312.

53. Schumacher S, Oeftiger L and Mrochen M. Equivalence of biomechanical changes induced by rapid and standard corneal cross-linking,
using riboflavin and ultraviolet radiation. *Invest Ophthalmol Vis Sci* 2011; 52: 9048–9052.

54. Hammer A, Richoz O, Arba Mosquera S, et al. Corneal biomechanical properties at different corneal cross-linking (CXL) irradiances. *Invest Ophthalmol Vis Sci* 2014; 55: 2881–2884.

55. Hashemi H, Ambrosio R Jr, Vinciguerra R, et al. Two-year changes in corneal stiffness parameters after accelerated corneal cross-linking. *J Biomech* 2019; 93: 209–212.

56. Aldahlawi N, Hayes S, O’Brart D, et al. Standard versus accelerated riboflavin/ultraviolet corneal cross-linking: resistance against enzymatic digestion. *J Cataract Refract Surg* 2015; 41: 1989–1996.

57. Aldahlawi N, Hayes S, O’Brart D, et al. Enzymatic resistance of corneas crosslinked using riboflavin in conjunction with low energy, high energy, and pulsed UVA irradiation modes. *Invest Ophthalmol Vis Sci* 2016; 57: 1547–1552.

58. Wernli J, Schumacher S, Spoerl E, et al. The efficacy of corneal cross-linking shows a sudden decrease with very high intensity UV light and short treatment time. *Invest Ophthalmol Vis Sci* 2013; 54: 1176–1180.

59. Shetty R, Pahuja NK, Nuijts RM, et al. Current protocols of corneal collagen cross-linking: visual, refractive, and tomographic outcomes. *Am J Ophthalmol* 2015; 160: 243–249.

60. Hashemi H, Fotouhi A, Miraftab M, et al. Short-term comparison of accelerated and standard methods of corneal collagen crosslinking. *J Cataract Refract Surg* 2015; 41: 533–540.

61. Hashemi H, Mohabibi M and Asgari S. Standard and accelerated corneal cross-linking long-term results: a randomized clinical trial. *Eur J Ophthalmol* 2020; 30: 650–657.

62. McCall A, Kraft S, Edelhauser H, et al. Mechanisms of corneal tissue cross-linking in response to treatment with topical riboflavin and long-wavelength ultraviolet radiation (UVA). *Invest Ophthalmol Vis Sci* 2010; 51: 129–138.

63. Kymionis GD, Tsoulnaras KI, Grentzelos MA, et al. Evaluation of corneal stromal demarcation line depth following standard and a modified-accelerated collagen cross-linking protocol. *Am J Ophthalmol* 2014; 158: 671–675.e671.

64. Sherif AM. Accelerated versus conventional corneal collagen cross-linking in the treatment of mild keratoconus: a comparative study. *Clin Ophthalmol* 2014; 8: 1435–1440.

65. Thaware OC and Huang D. Enrichment of oxygen concentration over simulated corneal surface through noncontact oxygen delivery device. *J Refract Surg* 2020; 36: 613–616.

66. Krueger RR, Herekar S and Spoerl E. First proposed efficacy study of high versus standard irradiance and fractionated riboflavin/ultraviolet a cross-linking with equivalent energy exposure. *Eye Contact Lens* 2014; 40: 353–357.

67. Mazzotta C, Traversi C, Paradiso AL, et al. Pulsed light accelerated crosslinking versus continuous light accelerated crosslinking: one-year results. *J Ophthalmol* 2014; 2014: 604731.

68. Moramarco A, Iovieno A, Sartori A, et al. Corneal stromal demarcation line after accelerated crosslinking using continuous and pulsed light. *J Cataract Refract Surg* 2015; 41: 2546–2551.

69. Peyman A, Nouralishahi A, Hafezi F, et al. Stromal demarcation line in pulsed versus continuous light accelerated corneal cross-linking for keratoconus. *J Refract Surg* 2016; 32: 206–208.

70. Said DG, Ross AR, Messina M, et al. Localised corneal haze and scarring following pulsed accelerated collagen cross-linking for keratoconus. Eye 2019; 33: 167–168.

71. Mazzotta C, Traversi C, Caragliu S, et al. Pulsed vs continuous light accelerated corneal collagen crosslinking: in vivo qualitative investigation by confocal microscopy and corneal OCT. *Eye (Lond)* 2014; 28: 1179–1183.

72. Merwald H, Klosner G, Kokesch C, et al. UVA-induced oxidative damage and cytotoxicity depend on the mode of exposure. *J Photochem Photobiol B* 2005; 79: 197–207.

73. Mazzotta C, Baiocchi S, Bagaglia SA, et al. Accelerated 15 mW pulsed-light crosslinking to treat progressive keratoconus: two-year clinical results. *J Cataract Refract Surg* 2017; 43: 1081–1088.

74. Belviranli S and Oltulu R. Efficacy of pulsed-light accelerated crosslinking in the treatment of progressive keratoconus: two-year results. *Eur J Ophthalmol* 2020; 30: 1256–1260.

75. Ziaei M, Gokul A, Vellara H, et al. Prospective two-year study of clinical outcomes following epithelium-off pulsed versus continuous accelerated corneal crosslinking for keratoconus. *Clin Exp Ophthalmol* 2019; 47: 980–986.

76. Gore DM, Leucci MT, Koay S-y, et al. Accelerated pulsed high-fluence corneal crosslinking for progressive keratoconus. *Am J Ophthalmol* 2021; 221: 9–16.

77. Sachdev GS, Ramamurthy S, Soundariya B, et al. Comparative analysis of safety and efficacy of
topography-guided customized cross-linking and standard cross-linking in the treatment of progressive keratoconus. *Cornea* 2021; 40: 188–193.

78. Greenstein SA, Shah VP, Fry KL, et al. Corneal thickness changes after corneal collagen crosslinking for keratoconus and corneal ectasia: one-year results. *J Cataract Refract Surg* 2011; 37: 691–700.

79. Ehmke T, Seiler TG, Fischinger I, et al. Comparison of corneal riboflavin gradients using dextran and HPMC solutions. *J Refract Surg* 2016; 32: 798–805.

80. Rechichi M, Mazzotta C, Daya S, et al. Intraoperative OCT pachymetry in patients undergoing dextran-free riboflavin UVA accelerated corneal collagen crosslinking. *Curr Eye Res* 2016; 41: 1310–1319.

81. Rosenblat E and Hersh PS. Intraoperative corneal thickness change and clinical outcomes after corneal collagen crosslinking: standard crosslinking versus hypotonic riboflavin. *J Cataract Refract Surg* 2016; 42: 596–605.

82. Zaheer N, Khan WA, Khan S, et al. Comparison of changes in central corneal thickness during corneal collagen cross-linking, using isotonic riboflavin solutions with and without dextran, in the treatment of progressive keratoconus. *Cornea* 2018; 37: 340–346.

83. Hagem AM, Thorsrud A, Sandvik GF, et al. Randomized study of collagen cross-linking with conventional versus accelerated UVA irradiation using riboflavin with hydroxypropyl methylcellulose: two-year results. *Cornea* 2019; 38: 203–209.

84. Hayes S, O’Brart DP, Lamdin LS, et al. Effect of complete epithelial debridement before riboflavin-ultraviolet-A corneal collagen crosslinking therapy. *J Cataract Refract Surg* 2008; 34: 657–661.

85. Gore DM, O’Brart D, French P, et al. Transepithelial riboflavin absorption in an ex vivo rabbit corneal model. *Invest Ophthalmol Vis Sci* 2015; 56: 5006–5011.

86. Samaras K, O’Brart D P, Douth J, et al. Effect of epithelial retention and removal on riboflavin absorption in porcine corneas. *J Refract Surg* 2009; 25: 771–775.

87. Cha SH, Lee JS, Oum BS, et al. Corneal epithelial cellular dysfunction from benzalkonium chloride (BAC) in vitro. *Clin Exp Ophthalmol* 2004; 32: 180–184.

88. Hayes S, Morgan SR, O’Brart DP, et al. A study of stromal riboflavin absorption in ex vivo porcine corneas using new and existing delivery protocols for corneal cross-linking. *Acta Ophthalmol* 2016; 94: e109–e117.

89. Aldahlawi NH, Hayes S, O’Brart DPS, et al. An investigation into corneal enzymatic resistance following epithelium-off and epithelium-on corneal cross-linking protocols. *Exp Eye Res* 2016; 153: 141–151.

90. Filippello M, Stagni E and O’Brart D. Transepithelial corneal collagen crosslinking: bilateral study. *J Cataract Refract Surg* 2012; 38: 283–291.

91. Caporossi A, Mazzotta C, Paradiso AL, et al. Transepithelial corneal collagen crosslinking for progressive keratoconus: 24-month clinical results. *J Cataract Refract Surg* 2013; 39: 1157–1163.

92. Gatziosuas Z, Raiskup F, O’Brart D, et al. Transepithelial corneal cross-linking using an enhanced riboflavin solution. *J Refract Surg* 2016; 32: 372–377.

93. Kobashi H, Rong SS and Ciolino JB. Transepithelial versus epithelium-off corneal crosslinking for corneal ectasia. *J Cataract Refract Surg* 2018; 44: 1507–1516.

94. Henriquez MA, Hernandez-Sahagun G, Camargo J, et al. Accelerated epi-on versus standard epi-off corneal collagen cross-linking for progressive keratoconus in pediatric patients: five years of follow-up. *Cornea* 2020; 39: 1493–1498.

95. Zaheryani SMS, Movahedan H, Salouti R, et al. Corneal collagen cross-linking using epithelium disruptor instrument in progressive keratoconus. *J Curr Ophthalmol* 2020; 32: 256–262.

96. Bikbova G and Bikbov M. Transepithelial corneal collagen cross-linking by iontophoresis of riboflavin. *Acta Ophthalmol* 2014; 92: e30–e34.

97. Cassagne M, Laurent C, Rodrigues M, et al. Iontophoresis transcorneal delivery technique for transepithelial corneal collagen crosslinking with riboflavin in a rabbit model. *Invest Ophthalmol Vis Sci* 2016; 57: 594–603.

98. Lombardo M, Serrao S, Lombardo G, et al. Two-year outcomes of a randomized controlled trial of transepithelial corneal crosslinking with iontophoresis for keratoconus. *J Cataract Refract Surg* 2019; 45: 992–1000.

99. Bikbova G and Bikbov M. Standard corneal collagen crosslinking versus transepithelial iontophoresis-assisted corneal crosslinking, 24 months follow-up: randomized control trial. *Acta Ophthalmol* 2016; 94: e600–e606.
100. Buzzonetti L, Petrocelli G, Valente P, et al. Iontophoretic transepithelial collagen cross-linking versus epithelium-off collagen cross-linking in pediatric patients: 3-year follow-up. Cornea 2019; 38: 859–863.

101. O’Brart NAL, O’Brart DPS, Aldahlawi NH, et al. An investigation of the effects of riboflavin concentration on the efficacy of corneal cross-linking using an enzymatic resistance model in porcine corneas. Invest Ophthalmol Vis Sci 2018; 59: 1058–1065.

102. Deshmukh R, Hafezi F, Kymionis GD, et al. Current concepts in crosslinking thin corneas. Indian J Ophthalmal 2019; 67: 8–15.

103. Hafezi F, Mrochen M, Iseli HP, et al. Collagen crosslinking with ultraviolet-A and hypoosmolar riboflavin solution in thin corneas. J Refract Surg 2009; 35: 621–624.

104. Hafezi F. Limitation of collagen cross-linking with hypoosmolar riboflavin solution: failure in an extremely thin cornea. Cornea 2011; 30: 917–919.

105. Spadea L and Mencucci R. Transepithelial corneal collagen cross-linking in ultrathin keratoconic corneas. Clin Ophthalmal 2012; 6: 1785–1792.

106. Akbar B, Intisar-Ul-Haq R, Ishaq M, et al. Transepithelial corneal crosslinking in treatment of progressive keratoconus: 12 months’ clinical results. Pak J Med Sci 2017; 33: 570–575.

107. Kymionis GD, Diakonis VF, Coskunseven E, et al. Customized pachymetric guided epithelial debridement for corneal collagen cross linking. BMC Ophthalmal 2009; 9: 10.

108. Cagil N, Sarac O, Can GD, et al. Outcomes of corneal collagen crosslinking using a customized epithelial debridement technique in keratoconic eyes with thin corneas. Int Ophthalmal 2017; 37: 103–109.

109. Mazzotta C and Ramovecchi V. Customized epithelial debridement for thin ectatic corneas undergoing corneal cross-linking: epithelial island cross-linking technique. Clin Ophthalmal 2014; 8: 1337–1343.

110. Jacob S, Kumar DA, Agarwal A, et al. Contact lens-assisted collagen cross-linking (CACXL): a new technique for cross-linking thin corneas. J Refract Surg 2014; 30: 366–372.

111. Knyazer B, Kormas RM, Chorny A, et al. Corneal cross-linking in thin corneas: 1-year results of accelerated contact lens-assisted treatment of keratoconus. J Refract Surg 2019; 35: 642–648.

112. Wollensak G, Spörl E and Herbst H. Biomechanical efficacy of contact lens-assisted collagen cross-linking in porcine eyes. Acta Ophthalmal 2019; 97: e84–e90.

113. Sachdev MS, Gupta D, Sachdev G, et al. Tailored stromal expansion with a refractive lenticule for crosslinking the ultrathin cornea. J Cataract Refract Surg 2015; 41: 918–923.

114. Cagini C, Riccitelli F, Messina M, et al. Epithelium-off-lenticule-on corneal collagen cross-linking in thin keratoconic corneas. Int Ophthalmal 2020; 40: 3403–3412.

115. Brekelmans J, Veugen J, Rieff K, et al. Enzymatic digestion of porcine corneas cross-linked by hypo- and hyperosmolar formulations of riboflavin/ultraviolet A or WST11/near-infrared light. Transl Vis Sci Technol 2020; 9: 4.

116. Brekelmans J. Long-term biomechanical and histologic results of WST-D/NIR corneal stiffening in rabbits, up to 8 months follow-up. Invest Ophthalmal Vis Sci 2017; 58: 4089–4095.

117. Marcovich AL, Brandis A, Daphna O, et al. Stiffening of rabbit corneas by the bacteriochlorophyll derivative WST11 using near infrared light. Invest Ophthalmal Vis Sci 2012; 53: 6378–6388.

118. Hayes S, Aldahlawi N, Marcovich AL, et al. The effect of bacteriochlorophyll derivative WST-D and near infrared light on the molecular and fibrillar architecture of the corneal stroma. Sci Rep 2020; 10: 9836.

119. Kanellopoulos AJ. Ten-year outcomes of progressive keratoconus management with the Athens Protocol (topography-guided partial-refraction PRK combined with CXL). J Refract Surg 2019; 35: 478–483.

120. Saleem MIH, Ibrahim Elzembely HA, AboZaid MA, et al. Three-year outcomes of cross-linking PLUS (combined cross-linking with femtosecond laser intracorneal ring segments implantation) for management of keratoconus. J Ophthalmal 2018; 2018: 6907573.

121. Bikbova G, Kazakbaeva G, Bikbov M, et al. Complete corneal ring (MyoRing) implantation versus MyoRing implantation combined with corneal collagen crosslinking for keratoconus: 3-year follow-up. Int Ophthalmal 2018; 38: 1285–1293.

122. Zhu AY, Jun AS and Soiberman US. Combined protocols for corneal collagen cross-linking with photorefractive surgery for refractive management of keratoconus: update on techniques and review of literature. Ophthalmal Ther 2019; 8: 15–31.